Press release
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Clinical Trials Assessment 2024: FDA Approvals, Drugs, Clinical Trials, Therapeutic Analysis, and Companies by DelveInsight
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Clinical Trials
Key Takeaways from the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Report
• DelveInsight's Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Human Immunodeficiency Virus Type 1 (HIV-1) Infection treatment.
• The leading companies working in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market include United BioPharma, Gilead sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics, and others.
• Promising Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapies in the various stages of development include B/F/TAF, TDF/3TC/EFV, ISL, DOR, Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC), Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), MK-8591A, and others.
• April 2024: ST Pharma Co. Ltd- A Phase 2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Investigate the Antiviral Effect, Safety, Tolerability, and Pharmacokinetics of STP0404 in Treatment-Naïve Adults With HIV-1 Infection.
• April 2024: Merck Sharp & Dohme LLC- A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study.
• April 2024:- Gilead Sciences- An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1.
Request a sample and discover the recent advances in Human Immunodeficiency Virus Type 1 (HIV-1) Infection Treatment Drugs @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Report- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Human Immunodeficiency Virus Type 1 (HIV-1) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Overview
HIV-1 is the most common type of Human Immunodeficiency Virus. It attacks the body's immune system. The virus destroys CD4 cells. CD4 cells help the body to fight infections. HIV-1 can severely damage immune system and lead to Acquired Immune Deficiency Syndrome (AIDS). Infection with HIV type 1 (HIV-1) typically occurs across mucosal surfaces or by direct inoculation.
Find out more about Human Immunodeficiency Virus Type 1 (HIV-1) Infection Therapeutics Assessment @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Emerging Drugs Profile
• UB421: United BioPharma
• Islatravir (MK-8591): Merck Sharp & Dohme
• PRO140: CytoDyn Inc.
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Human Immunodeficiency Virus Type 1 (HIV-1) Infection. The Human Immunodeficiency Virus Type 1 (HIV-1) Infection companies which have their Human Immunodeficiency Virus Type 1 (HIV-1) Infection drug candidates in the most advanced stage, i.e. phase III include, United Biopharma.
DelveInsight's Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Intramuscular
• Subcutaneous
• Molecule Type
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Small molecule
• Product Type
Learn more about the emerging Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapies @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Clinical Trials Assessment- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Report
• Coverage- Global
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Companies- United BioPharma, Gilead sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics, and others.
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapies- B/F/TAF, TDF/3TC/EFV, ISL, DOR, Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC), Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), MK-8591A, and others.
Dive deep into rich insights for new drugs for Human Immunodeficiency Virus Type 1 (HIV-1) Infection Treatment, Visit @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Human Immunodeficiency Virus Type 1 (HIV-1) Infection - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Collaboration Deals
9. Late Stage Products (Phase III)
10. UB421: United BioPharma
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. PRO140: CytoDyn Inc.
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Companies
20. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Products
21. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Unmet Needs
22. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Market Drivers and Barriers
23. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Future Perspectives and Conclusion
24. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Analyst Views
25. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Companies
26. Appendix
For further information on the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline therapeutics, reach out to Human Immunodeficiency Virus Type 1 (HIV-1) Infection Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
Contact Us:
Ankit Nigam
Marketing Manager
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Human Immunodeficiency Virus Type 1 (HIV-1) Infection Clinical Trials Assessment 2024: FDA Approvals, Drugs, Clinical Trials, Therapeutic Analysis, and Companies by DelveInsight here
News-ID: 3564474 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
